Month: July 2024

REPEAT: Eric Sprott acquires a substantial stake in Cerro de Pasco Resources

Written by Customer Service on July 9, 2024. Posted in Public Companies.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES MONTRÉAL, July 09, 2024 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (CSE: CDPR) (OTCPK: GPPRF) (FRA: N8HP) (“CDPR” or the “Corporation”) is pleased to announce the closing of its previously announced non-brokered private placement, for total aggregate gross proceeds of $3,298,000 (the “Offering”). CDPR issued 32,980,000 units of the Corporation (“Units”) at a price of $0.10 per Unit, each consisting of one common share (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles its holder to purchase one Common Share at an exercise price of $0.15 per Common Share for a period of 24 months, subject to acceleration in certain circumstances (see news release...

CytoDyn Announces Settlement with Amarex Clinical Research LLC

Written by Customer Service on July 9, 2024. Posted in Public Companies.

Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has settled its lawsuit against Amarex Clinical Research LLC (“Amarex”), the Company’s former Contract Research Organization (“CRO”). The material terms of the settlement are as follows: (i) Amarex will pay $12,000,000 to CytoDyn, $10,000,000 was paid upon execution of the agreement and the remainder to be paid within the next 12 months; (ii) the surety bond, valued at $6,500,000, will be released...

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial

Written by Customer Service on July 9, 2024. Posted in Public Companies.

Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical Trial. The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY® Endovascular Robotic Surgical System. BRAINTREE, Mass., July 09, 2024 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that Baptist Hospital of Miami, which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute, has completed its first clinical procedure in a patient utilizing the LIBERTY® Endovascular Robotic Surgical System. The clinical case was performed shortly after last week’s announcement regarding the participation of Baptist Hospital of Miami as a clinical trial site. Baptist Hospital is the second clinical site to perform a clinical...

Conversational Artificial Intelligence (AI) Market Forecast to Grow at 22.60% CAGR from 2024 to 2031 | SkyQuest Technology

Written by Customer Service on July 9, 2024. Posted in Mergers And Acquisitions.

Westford, USA, July 09, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Global Conversational Artificial Intelligence (AI) Market will attain a value of USD 48.81 Billion by 2031, with a CAGR of 22.60% during the forecast period (2024-2031). The conversational AI market is booming due to many technological advancements in the field of AI. Today there are several conversational AI solution providers in the market who are responsible for developing chatbots and virtual assistants on open platforms with few user-specific features. The market growth is also rapidly increasing due to omnichannel deployment and easy affordability of chatbot. Growing use of AI-based customer services additionally fuels the industry growth. In the past few years’ social media platforms such as Facebook, Telegram, Twitter, Tumblr, and Skype have implemented...

Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Accounts

Written by Customer Service on July 9, 2024. Posted in Mergers And Acquisitions.

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of several key accounts in the UK manufacturing sector. This announcement follows recent successes in the warehouse and logistics, transport and infrastructure, and retail sectors as the Company’s growth momentum continues. Recent additions to INBS’ customer account portfolio include three major manufacturers, each with unique needs and challenges in maintaining workplace safety. A leading automotive components manufacturer with five sites and 1,200 employees has transitioned from third-party urine testing to the Intelligent Fingerprinting Drug Screening System....

Netcoins Announces Unaudited Q2 Results

Written by Customer Service on July 9, 2024. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”) (CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins, Blockchain Intelligence Group, and TerraZero is pleased to report Netcoins unaudited Q2 2024 results. All figures are in Canadian dollars (CAD) unless otherwise stated.Q2 2024 recorded quarterly revenue of $2.1 million, an increase of over 100% compared to Q2 2023Netcoins crypto trading platform processed approximately $158 million in crypto trading volume in Q2 2024, compared to $56.5 million in Q2 2023Netcoins total cash, digital assets, and investments were approximately $15.3 million as at June 30, 2024Netcoins Assets Under Custody were over $147 million as at June 30, 2024“Netcoins has consistently...

Clene Announces 1-for-20 Reverse Stock Split

Written by Customer Service on July 9, 2024. Posted in Public Companies.

SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will effect a 1-for-20 reverse stock split at 12:01 a.m. Eastern Time, on July 11, 2024. Beginning with the opening of trading on July 11, 2024, Clene’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 185634201 and the Company’s existing trading symbol “CLNN.” The CUSIP number for the Company’s publicly traded warrants will not change. The reverse stock split...

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease

Written by Customer Service on July 9, 2024. Posted in Public Companies.

– Abiprubart Phase 2b clinical trial in Sjögren’s Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations – – Abiprubart clinical development in Sjögren’s Disease fully funded; company expects to remain cash flow positive on an annual basis – LONDON, July 09, 2024 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced that it has commenced enrollment of the Phase 2b clinical trial of abiprubart in Sjögren’s Disease. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction. “Sjögren’s Disease is a debilitating,...

Puma Exploration Consolidates Landholdings at Williams Brook

Written by Customer Service on July 9, 2024. Posted in Public Companies.

RIMOUSKI, Quebec, July 09, 2024 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is delighted to announce a strategic property acquisition, the “Moose Brook property.” The 28 claims (608 ha) fill a gap in the 100%-owned Williams Brook property, strengthening our position in the region (Figure 1-2). Puma Exploration is the biggest landholder in Northern New Brunswick and the most active explorer in the area. “This acquisition further adds to our considerable ground position in Northern New Brunswick. Over the past four years, we’ve completed many separate transactions to consolidate a patchwork of mining claims held by many landowners. Most mining claims had seen little to no modern exploration work and had never been worked as a whole. Our exploration programs...

Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024

Written by Customer Service on July 9, 2024. Posted in Public Companies.

SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be attending the JonesHealthcare Seaside Summit 2024 being held July 14-16, 2024, in Encinitas, CA. John Bencich, CEO of Achieve, will present on Monday, July 15, 2024, at 8:45 AM PDT. Following the presentation, he will also participate in a live panel discussion titled “Introducing Disruptive Products to Established Healthcare Markets—Commercial and Regulatory Considerations” at 10:00 AM PDT. The panel will be hosted by Justin Walsh, PhD, a Healthcare Research Analyst at JonesTrading Institutional Services LLC....

Month: July 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals